Research and Markets: The Immune/Inflammatory Pipeline - A Strategic Review

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/d0a0a2/the_immuneinflamm) has
announced the addition of Decision Resources, Inc.'s new report "The
Immune/Inflammatory Pipeline: A Strategic Review" to their offering.

The current immune/inflammatory pipeline is over 375 drugs strong, with
approximately 250 companies involved in these agents' development. Yet, despite
this robust pipeline size, Decision Resources analysts do not believe that any
one agent in development will significantly alter the way physicians treat their
patients with immune/inflammatory disorders. Nonetheless, opportunities exist
for companies that develop treatments for specific unmet needs in this
therapeutic area.

While these opportunities will not yield the kind of cross-indication
blockbuster returns previously seen in this therapeutic area, investing R&D
money in the immune/inflammatory area still seems worthwhile. Questions Answered
in This Report The immune/inflammatory market experienced steady growth from
2003 through 2008. What drug classes contributed most to this steady increase in
sales? What other factors play a role in market growth in this therapeutic
area?

* The failure rate of current biologics for rheumatoid arthritis (RA) and
similar indications is high enough to justify the need for more-efficacious
treatments. Does the pipeline feature novel agents with potential for higher
efficacy than current agents? Which indications within this therapeutic area are
drawing the most interest from developers?
* The immune/inflammatory therapeutic area is lucrative and will likely continue
to be so in the future. Which companies are the current market leaders? Which
companies are attempting to enter, grow, or defend their position in this
market?
* Replicating the success of today's immune/inflammatory agents presents a
challenge to developers of novel treatments. How do regulatory requirements
complicate R&D efforts? How can drug developers working in this area maximize
their chances of success? market: 2008 sales; leading drug classes;
market-leading companies; commercial position of leading agents.
* The immune/inflammatory disease pipeline: Number of agents in development;
disease focus; active companies; profiles of Novartis, GlaxoSmithKline, and
Pfizer; mechanisms of action; company type; phase analysis; novel formulations
versus reformulations; smallmolecule drugs versus biologics.
* Immune/inflammatory diseases focused on in this report: Ankylosing
spondylitis; asthma; chronic obstructive pulmonary disease (COPD); Crohn's
disease (CD); psoriasis; psoriatic arthritis; rheumatoid arthritis (RA);
Sjogren's syndrome; systemic lupus erythematosus (SLE); ulcerative colitis (UC).

* Challenges in immune/inflammatory diseases: Regulatory issues; challenging
first-line therapies.
* Opportunities in immune/inflammatory diseases: Working to tap unmet needs;
gaining access to niche indications.

Key Topics Covered:

* Executive Summary
* Strategic Considerations
* Stakeholder Implications
* Introduction
* The Immune/Inflammatory Disease Pipeline
* Emerging Agents Targeting Diseases with Unmet Needs
* Companies Developing Immune/Inflammatory Disease Agents
* Current Market-Leading Companies
* Challenges and Opportunities in the Immune/Inflammatory Disease Market
* Current Market-Leading Products Pose a High Hurdle for Emerging Therapies
* But Also Leave Gaps That Provide Opportunities for Emerging Agents
* Opportunities in Rheumatoid Arthritis
* Opportunities in Chronic Obstructive Pulmonary Disease
* Opportunities in Systemic Lupus Erythematosus
* Outlook for Emerging Agents
* Current Market Statistics
* Pipelines and Companies
* Will Mergers & Acquisitions Continue to Move the Market?
* Will Market-Leading Companies Continue to Dominate?

Companies Mentioned:

* Abbott Laboratories
* Amgen
* Array BioPharma
* AstraZeneca
* Boehringer Ingelheim
* Centocor
* CombinatoRx
* Dong-A Pharmaceutical
* Eisai
* Eli Lilly
* Genentech
* GlaxoSmithKline
* Johnson & Johnson
* Medimmune
* Merck & Co.
* Merck Serono
* Mitsubishi Tanabe Pharma
* Novartis
* Pfizer
* Roche
* Schering-Plough
* Takeda
* UCB
* Wyeth

For more information visit
http://www.researchandmarkets.com/research/d0a0a2/the_immuneinflamm

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
Fax (USA): 646-607-1907
Fax (International): +353-1-481-1716

Copyright Business Wire 2009